| M121 | (−)-MDO-NPA hydrochloride | | | pricing |
|
| Q102 | (−)-Quinpirole hydrochloride ≥98% (HPLC), solid | The putative D2 dopamine receptor agonist quinpirole (LY 171,555) is the most widely used D2 agonist in in vivo and in vitro studies Active enantiomer of (±)-quinpirole. Quinpirole is a dopamine agonist with high affinity for the D2 and D3 dopamine receptor subtypes. Specific [3H]quinpirole binding in rat brain was saturable, and dependent on temperature, membrane concentration, sodium concentration and guanine nucleotides. Saturation analysis revealed high affinity binding characteristics (KD = 2.3 +/- 0.3 nM) which were confirmed by association-dissociation kinetics. The regional distribution of [3H]quinpirole binding sites roughly paralleled the distribution of [3H]spiperone binding sites, with greatest densities present in the striatum, nucleus accumbens and olfactory tubercles. A variety of drugs, most notably monoamine oxidase inhibitors (MAOls), inhibit the binding of [3H]quinpirole, but not [3H]spiperone or [3H](-)N-n-Propylnorapomorphine, in rat striatal membranes by a mechanism that does not appear to involve the enzymatic activity of MAO. Clinically antidepressant MAOIs exhibited selectivity between sites labeled by [3H]quinpirole and [3H]spiperone as did a number of structurally related propargylamines and N-acylethylenediamine derivatives and other drugs such as debrisoquin and phenylbiguanide. The MAOIs clorgyline and Ro 41-1049 were the most potent. MAOIs interact with a novel binding site that is labeled by [3H]quinpirole or that modulates [3H]quinpirole binding. This site may be associated with D2-like dopamine receptors.
|  | pricing |
|
| D002 | (±)-2-Amino-6,7-dihydroxy-1,2,3,4-tetrahydronaphthalene hydrobromide solid | Dopamine receptor agonist.
|  | pricing |
|
| S143 | (±)-6-Chloro-PB hydrobromide ≥98% (HPLC), solid | (+/-)-6-Chloro-PB HBr is a full D1 dopamine receptor agonist.
|  | pricing |
|
| H8653 | (±)-7-Hydroxy-2-(di-n-propylamino)tetralin hydrobromide | A selective D3 dopamine receptor agonist (Kd <1nM); has much weaker affinity for other dopamine receptor subtypes.
|  | pricing |
|
| P216 | (±)-PD 128,907 hydrochloride solid, ≥98% (HPLC) | Selective D3 dopamine receptor agonist.
|  | pricing |
|
| P105 | (±)-PPHT hydrochloride ≥98% (HPLC), solid | Potent D2 dopamine receptor agonist.
A series of new dopamine (DA) receptor agonists, of the 2-aminotetralin group, i.e. N-0434, N-0437 and N-0734 were investigated in both in vivo and in vitro pharmacological test systems. In vivo, the reversal of the gamma-butyrolactone-induced increase in rat central DOPA biosynthesis rate was taken as a measure of presynaptic activity. The homovanillic acid (HVA) decrease, after intraperitoneal and after oral administration of the drugs was also taken as a measure of presynaptic activity. Postsynaptic activity was measured in two behavioural models, i.e. reserpine reversal and stereotypy induction. The effects of (±)-PPHT (N-0434) these drugs on noradrenaline and dopamine turnover (alpha-MpT method) were studied in addition. The results indicate that all three compounds N-0434 ((±)-PPHT), N-0437 and N-0734 are potent and selective DA agonists that lack significant alpha 2 activity.
|  | pricing |
|
| Q111 | (±)-Quinpirole dihydrochloride solid | D2-like dopamine receptor agonist that possesses some activity at D3 sites.
|  | pricing |
|
| D047 | (±)-SKF-38393 hydrochloride crystalline, ≥98% (HPLC) | D1 Dopamine receptor agonist.
|  | pricing |
|
| P183 | (+)-PD 128,907 hydrochloride >97%, solid | Selective D3 dopamine receptor agonist.
| | pricing |
|
| S101 | (R)-(+)-SKF-38393 hydrochloride ≥98% (HPLC), solid | D1 dopamine receptor agonist; active enantiomer of (±)-SKF-38393.
|  | pricing |
|
| S178 | (R)-SKF-82957 hydrobromide solid | Selective D1 dopamine receptor agonist.
|  | pricing |
|
| P103 | (S)-(−)-3-(3-Hydroxyphenyl)-N-propylpiperidine hydrochloride ≥98% (HPLC), solid | Dopamine autoreceptor agonist; postsynaptic dopamine receptor antagonist.
| | pricing |
|
| B2134 | 2-Bromo-α-ergocryptine methanesulfonate salt solid | Agonist at D2 and D3 dopamine receptors; inhibits prolactin secretion.
|  | pricing |
|
| A8852 | A-68930 hydrochloride ≥98% (HPLC), solid | Selective D1 dopamine receptor agonist
|  | pricing |
|
| A255 | A-77636 hydrochloride hydrate ≥98% (HPLC), solid | Potent, orally active D1 dopamine receptor agonist.
|  | pricing |
|
| A5111 | ABT-724 trihydrochloride ≥98% (HPLC)  | |  | pricing |
|
| B9308 | BP897 >98% (HPLC), solid | Partially selective D3 dopamine receptor agonist.
|  | pricing |
|
| C130 | Chloro-APB hydrobromide solid | Full D1 dopamine receptor agonist.
|  | pricing |
|
| D5886 | Deoxyepinephrine hydrochloride ≥95%, solid | Dopamine receptor agonist, α-adrenoceptor agonist.
|  | pricing |
|
| H8502 | Dopamine hydrochloride | Neurotransmitter.
|  | pricing |
|
| F1041 | FAUC 73 liquid | Selective, potent and nonaromatic D3 dopamine receptor agonist
|  | pricing |
|
| F6800 | Fenoldopam monohydrobromide ≥98% | Fenoldopam is a selective dopamine agonist that is being considered for the parenteral treatment of systemic hypertension. In both an oral and parenteral form, fenoldopam causes peripheral vasodilation by stimulating dopamine-1 adrenergic receptors. Intravenous fenoldopam may provide advantages over sodium nitroprusside because it can induce both a diuresis and natriuresis, is not light sensitive, and is not associated with cyanide toxicity. There is no evidence for rebound hypertension after discontinuation of fenoldopam infusion.
| | pricing |
|
| S168 | N-Allyl-(±)-SKF-38393 hydrobromide solid, ≥98% (HPLC) | Centrally active D1 dopamine receptor agonist.
|  | pricing |
|
| C7230 | N-[2-(4-(4-Chlorophenyl)piperazin-1-yl)ethyl]-3-methoxybenzamide solid | Potent, selective D4 dopamine receptor ligand.
|  | pricing |
|
| P233 | PD 168,077 maleate salt powder | Selective D4 dopamine receptor agonist.
|  | pricing |
|
| P8828 | Pergolide mesylate salt ≥98%, solid | Dopaminergic agonist; suppresses pituitary secretion of prolactin; anti-Parkinsonian agent.
|  | pricing |
|
| P9233 | Piribedil maleate salt | A direct dopamine agonist; may be selective for the D3 subtype; no significant affinity for D1 receptors.
|  | pricing |
|
| Q110 | Quinelorane dihydrochloride crystalline | D2 dopamine receptor agonist; 2-aminopyridine analog of quinpirole.
|  | pricing |
|
| D030 | R(−)-2,10,11-Trihydroxy-N-propyl-noraporphine hydrobromide hydrate solid | Potent, selective D2 dopamine receptor agonist.
|  | pricing |
|
| D029 | R(−)-2,10,11-Trihydroxyaporphine hydrobromide >97%, small crystals | Dopamine receptor agonist.
|  | pricing |
|
| D027 | R(−)-Propylnorapomorphine hydrochloride solid | Highly potent and selective D2 dopamine receptor agonist.
|  | pricing |
|
| D003 | R(−)-Apocodeine hydrochloride solid | Dopamine receptor agonist; apomorphine metabolite.
|  | pricing |
|
| D040 | R(–)-Norapomorphine hydrobromide solid | Dopamine receptor agonist.
|  | pricing |
|
| P102 | R(+)-3-(3-Hydroxyphenyl)-N-propylpiperidine hydrochloride solid | D2 dopamine receptor agonist. Also functions as σ1 receptor antagonist with essentially no affinity for the phencylidine site on the NMDA receptor.
|  | pricing |
|
| B135 | R(+)-6-Bromo-APB hydrobromide solid | D1 Dopamine receptor agonist; more potent enantiomer.
|  | pricing |
|
| H168 | R(+)-7-Hydroxy-DPAT hydrobromide >98%, solid | Selective D3 dopamine receptor agonist; active enantiomer of (±)-7-hydroxy-DPAT
| | pricing |
|
| S179 | R(+)-SKF-81297 hydrobromide ≥98% (HPLC), solid | R(+)-SKF-81297 hydrobromide is a selective D1 dopamine receptor agonist.
|  | pricing |
|
| A4393 | R-(−)-Apomorphine hydrochloride hemihydrate calcined, ≥98.5% | Nonselective dopamine agonist; causes nausea and emesis.
|  | pricing |
|
| R2530 | Ropinirole hydrochloride solid, ≥98% (HPLC) | An agonist at the D2 and D3 dopamine receptor subtypes, binding with higher affinity to D3 than to D2 or D4. It has negligible effect on D1-receptors. It has medium in vitro affinity to opioid receptors. Ropinirole is said to have virtually no affinity to 5-HT1, 5-HT2, benzodiazepine, GABA, muscarinic, α1-, α2-, and β-adrenoreceptors. Used as antiparkinsonian drug.
Selective D2 dopamine receptor agonist, antiparkinsonian
|  | pricing |
|
| R9281 | Rotigotine hydrochloride ≥98% (HPLC) | Rotigotine is an anti-Parkinsonian agent, and a D2/D3 Dopamine agonist. Rotigotine is a non-ergot (or non-ergotamine) dopamine agonist drug and is indicated for the treatment of Parkinson's disease. Quinpirole (Q-102), the golden starndard of D2 agonist, is about 50-fold less potent than the racemic rotigotine as reported.
|  | pricing |
|
| B136 | S(−)-6-Bromo-APB hydrobromide solid | Weak D1 dopamine receptor agonist; less potent enantiomer.
|  | pricing |
|
| T165 | S(+)-Terguride solid | Ergot derivative; dehydrogenated analog of lisuride; D2 dopamine receptor partial agonist.
|  | pricing |
|
| S102 | S-(−)-SKF-38393 hydrochloride solid | D1 dopamine receptor agonist; less active enantiomer of (±)-SKF-38393.
|  | pricing |
|
| S2941 | SKF-75670 hydrobromide >98% (HPLC), solid | Atypical D1 dopamine receptor agonist. Displays antagonist activity in vitro and agonist activity in vivo.
|  | pricing |
|
| S3191 | SKF-83565 hydrobromide >98% (HPLC), solid | Atypical D1 dopamine receptor agonist. Displays antagonist activity in vitro and agonist activity in vivo.
|  | pricing |
|
| S2816 | SKF-83959 hydrobromide >98% (HPLC), solid | D1 dopamine receptor agonist. Displays antagonist activity in vitro and agonist activity in vivo.
|  | pricing |
|
| S3316 | SKF-89145 hydrobromide >98% (HPLC), solid | D1 dopamine receptor agonist.
|  | pricing |
|
| S3066 | SKF-89626 hydrobromide >98% (HPLC), solid | D1 dopamine receptor agonist.
|  | pricing |
|
| T2879 | Tyramine hydrochloride ≥98% | Can enter catecholaminergic terminals and be released as a false transmitter.1
|  | pricing |
|
| P0618 | cis-8-Hydroxy-3-(n-propyl)-1,2,3a,4,5,9b-hexahydro-1H-benz[e]indole hydrobromide ≥98% (HPLC), solid | D3 dopamine receptor agonist.
|  | pricing |
|
| D017 | m-Tyramine hydrochloride solid, ≥98% (HPLC) | Dopamine receptor agonist; biological precursor to dopamine.
|  | pricing |
|
Product # 